Back to Search Results

7/1/2017

Lynch Syndrome

Author: Janeen Arbuckle M.D., PhD

Registered users can also download a PDF or listen to a podcast of this Pearl.
Log in now, or create a free account to access bonus Pearls features.

Mentor: Todd Jenkins MD

Editor: Elizabeth Ferries-Rowe

Lynch syndrome is an autosomal dominant hereditary cancer syndrome which commonly presents with colon cancer, endometrial cancer, or ovarian cancer.  It is also associated with cancers of the stomach, small bowel, hepatobiliary system, renal pelvis, and ureter.  Lynch syndrome is characterized by defects in genes involved in DNA mismatch repair such as MLH1, MSH2, MSH6, and PMS2, mutation of which results in microsatellite instability. Although Lynch syndrome is only responsible for approximately 2% of all colon and endometrial cancers, individuals with Lynch syndrome are at increased risk for the development of these cancers over their lifetime. The risk of cancer depends on the specific inherited gene mutation, with the risk of developing endometrial cancer ranging from 16-61% and the risk of developing colon cancer ranging from 18-61% by age 70.  Women with Lynch syndrome also have an increased risk of ovarian cancer by age 70 relative to the general population (5-10% vs 1.4%).

Women who are diagnosed with a Lynch syndrome-associated cancer should be screened.  This includes women who have:

  • Uterine or colorectal cancer prior to age 50
  • Two or more synchronous or sequential Lynch syndrome associated malignancies
  • Colorectal cancer with worrisome histologic features (e.g. tumor-infiltrating lymphocytes, signet-ring differentiation, etc.)

In addition, women with a personal history of uterine or colorectal cancer and a family history of a Lynch syndrome-associated malignancy may also warrant screening for Lynch syndrome.  Testing for Lynch syndrome can be done by germline DNA testing of the patient or by testing of the tumor for the expression of mismatch repair genes or for microsatellite instability.

Women with a family history of Lynch syndrome-associated cancers should also be screened.  Women who are at especially high risk are those with a first degree relative with a Lynch syndrome-associated cancer diagnosed prior to age 60. In addition, women with a known family history of Lynch syndrome should be offered referral to a genetic counselor regardless of degree of relation. Germline testing for Lynch syndrome-associated mutations may then be considered.

Women with confirmed Lynch syndrome should be offered surveillance for Lynch syndrome-associated malignancies and should be counseled on options for risk reduction.  Screening for colon cancer in women with Lynch syndrome includes colonoscopy every 1-2 years, starting between the ages of 20-25 or 2-5 years prior to the earliest cancer diagnosis in the family, whichever is earlier.  Screening for endometrial cancer should be done by endometrial biopsy every 1-2 years, starting between the ages of 30-35. Women should keep a menstrual calendar and have additional evaluation in the setting of abnormal bleeding.  No reliable screening testing has been validated for the early detection of ovarian cancer.  Risk reduction may be achieved in reproductive age women through the use of progesterone agents or combined oral contraceptives.  Risk reducing hysterectomy with bilateral salpingo-oophorectomy should be considered in women in their early to mid-40s or upon the completion of childbearing.

Further reading:

Committee on Practice Bulletins-Gynecology; Society of Gynecologic Oncology. ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol. 2014 Nov;124(5):1042-54. doi: 10.1097/01.AOG.0000456325.50739.72.

Giardiello FM, Allen JI, Axilbund JE, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-society Task Force on colorectal cancer. Am J Gastroenterol. 2014 Aug;109(8):1159-79. doi: 10.1038/ajg.2014.186. Epub 2014 Jul 22.

Provenzale D, Gupta S, Ahnen DJ, et al. Genetic/Familial High-Risk Assessment: Colorectal Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Aug;14(8):1010-30.

Initial approval July 2017. Reaffirmed January 2019

 

********** Notice Regarding Use ************

The Foundation for Exxcellence in Women’s Health, Inc (“Foundation”) is committed to accuracy and will review and validate all Pearls on an ongoing basis to reflect current practice.

This document is designed to aid practitioners in providing appropriate obstetric and gynecologic care. Recommendations are derived from major society guidelines and high quality evidence when available, supplemented by the opinion of the author and editorial board when necessary. It should not be construed as dictating an exclusive course of treatment or procedure to be followed.

Variations in practice may be warranted when, in the reasonable judgment of the treating clinician, such course of action is indicated by the condition of the patient, limitations of available resources, or advances in knowledge or technology. The Foundation reviews the articles regularly; however, its publications may not reflect the most recent evidence. While we make every effort to present accurate and reliable information, this publication is provided “as is” without any warranty of accuracy, reliability, or otherwise, either express or implied. The Foundation does not guarantee, warrant, or endorse the products or services of any firm, organization, or person. Neither the Foundation, the ABOG, SASGOG nor their respective officers, directors, members, employees, or agents will be liable for any loss, damage, or claim with respect to any liabilities, including direct, special, indirect, or consequential damages, incurred in connection with this publication or reliance on the information presented.

Copyright 2019 The Foundation for Exxcellence in Women's Health, Inc. All rights reserved.  No re-print, duplication or posting allowed without prior written consent.

 

Back to Search Results